Vanda Pharmaceuticals appoints chief commercial officer

Bob Repella joins US biopharmaceutical firm

Vanda Pharmaceuticals has named Bob Repella as senior vice president and chief commercial officer of the US biopharmaceutical firm that specialises in clinical-stage products for CNS disorders.

Repella has more than 25 years of experience in the biotech/pharmaceutical industry, including senior-level leadership roles in global marketing, sales, new product development and commercial operations.

Prior to joining Vanda, he was senior vice president of Pharmaceutical Operations for the Americas at Cephalon.

Before this, Repella was executive vice president and general manager of the Biopharma Business Unit for Wyeth Pharmaceuticals.

Earlier in his career, Repella held positions with Johnson & Johnson's McNeil Pharmaceutical Division, Merck & Co and Eli Lilly.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Regulatory
Latest EU drug approvals span range of health issues

Latest EU drug approvals span range of health issues

Cancer was again at the forefront of the NMEs reaching the market in 2015, but new drugs also benefited other disease areas. Dr Sarah Houlton looks at the latest therapeutic arrivals
Regulatory
Sleep disorders – tasimelteon

Sleep disorders – tasimelteon

Melatonin can be used to treat sleep disorders, but it has poor bioavailability, and has a half-life in the body of only about 15 minutes
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory
What Operation TrialBlazer means for CDMOs and CMC strategy

What Operation TrialBlazer means for CDMOs and CMC strategy

The FDA's new framework cuts Phase I data requirements, opens platform manufacturing data reuse and creates a new CRO/CDMO review role as HHS moves to close the gap with China's faster clinical trial pipeline — but how will this affect the pharma sector?
Manufacturing
Piramal Pharma Solutions highlights strong performance across more than 200 customer audits

Piramal Pharma Solutions highlights strong performance across more than 200 customer audits

Piramal Pharma Solutions completed more than 200 customer audits and received over 70 approvals from regulatory agencies across its global network over the past year, with strong overall outcomes
Regulatory
Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS

Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS

The clearance enables a first-in-human trial of the UCB-licensed remyelination candidate, marking the first GPR17 programme to reach clinical development for multiple sclerosis and related demyelinating diseases
Manufacturing
TurboFil introduces Benchtop Version of Precision Unidose and Bi-dose Vial Filler and Stoppering System

TurboFil introduces Benchtop Version of Precision Unidose and Bi-dose Vial Filler and Stoppering System

Company’s manual UDS/BDS Benchtop Vial Filler utilises same technique as its higher-volume automatic systems, simplifying lab-scale filling while easing downstream scale-up
Regulatory
What is ISO/IEC 17025 and why it matters for calibration

What is ISO/IEC 17025 and why it matters for calibration

As regulatory expectations continue to increase, particularly around data integrity and traceability, the question becomes less about collecting data, and more about trusting it
Subscribe now